Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events : the Belgian experience
Hydroxyurea (HU) is considered to be the most successful drug therapy for severe sickle cell disease (SCD). Nevertheless, questions remain regarding its benefits in very young children and its role in the prevention of cerebrovascular events. There were 127 SCD patients treated with no attempt to reach maximal tolerated doses who entered the Belgian Registry: 109 for standard criteria and 18 who were at risk of stroke only. During 426 patient-years of follow-up for patients with standard criteria, 3.3 acute chest syndromes, 1.3 cerebrovascular events, and 1.1 osteonecrosis per 100 patient-years were observed. A subgroup of 32 patients followed for 6 years experienced significant benefit over this period. In each subgroup of children (younger than 2 years, 2-5, 6-9, and 10-19 years) followed for 2 years, clinical and biologic changes were similar, except for children younger than 2 years who had no total hemoglobin increase and remained at risk of severe anemia. In 72 patients evaluated by transcranial Doppler studies (TCD), 34 patients were at risk of primary stroke and only 1 had a cerebrovascular event after a follow-up of 96 patient-years. These results confirm the benefit of HU, even in very young children, and its possible role in primary stroke prevention.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2005 |
|---|---|
| Erschienen: |
2005 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:105 |
|---|---|
| Enthalten in: |
Blood - 105(2005), 7 vom: 01. Apr., Seite 2685-90 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gulbis, Béatrice [VerfasserIn] |
|---|
| Themen: |
Antisickling Agents |
|---|
| Anmerkungen: |
Date Completed 03.05.2005 Date Revised 10.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM152675213 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM152675213 | ||
| 003 | DE-627 | ||
| 005 | 20231223062510.0 | ||
| 007 | tu | ||
| 008 | 231223s2005 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0509.xml |
| 035 | |a (DE-627)NLM152675213 | ||
| 035 | |a (NLM)15604217 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gulbis, Béatrice |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events |b the Belgian experience |
| 264 | 1 | |c 2005 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 03.05.2005 | ||
| 500 | |a Date Revised 10.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Hydroxyurea (HU) is considered to be the most successful drug therapy for severe sickle cell disease (SCD). Nevertheless, questions remain regarding its benefits in very young children and its role in the prevention of cerebrovascular events. There were 127 SCD patients treated with no attempt to reach maximal tolerated doses who entered the Belgian Registry: 109 for standard criteria and 18 who were at risk of stroke only. During 426 patient-years of follow-up for patients with standard criteria, 3.3 acute chest syndromes, 1.3 cerebrovascular events, and 1.1 osteonecrosis per 100 patient-years were observed. A subgroup of 32 patients followed for 6 years experienced significant benefit over this period. In each subgroup of children (younger than 2 years, 2-5, 6-9, and 10-19 years) followed for 2 years, clinical and biologic changes were similar, except for children younger than 2 years who had no total hemoglobin increase and remained at risk of severe anemia. In 72 patients evaluated by transcranial Doppler studies (TCD), 34 patients were at risk of primary stroke and only 1 had a cerebrovascular event after a follow-up of 96 patient-years. These results confirm the benefit of HU, even in very young children, and its possible role in primary stroke prevention | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antisickling Agents |2 NLM | |
| 650 | 7 | |a Hydroxyurea |2 NLM | |
| 650 | 7 | |a X6Q56QN5QC |2 NLM | |
| 700 | 1 | |a Haberman, David |e verfasserin |4 aut | |
| 700 | 1 | |a Dufour, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Christophe, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Vermylen, Christiane |e verfasserin |4 aut | |
| 700 | 1 | |a Kagambega, Faustin |e verfasserin |4 aut | |
| 700 | 1 | |a Corazza, Francis |e verfasserin |4 aut | |
| 700 | 1 | |a Devalck, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Dresse, Marie-Françoise |e verfasserin |4 aut | |
| 700 | 1 | |a Hunninck, Kathleen |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, Axel |e verfasserin |4 aut | |
| 700 | 1 | |a Le, Phu Quoc |e verfasserin |4 aut | |
| 700 | 1 | |a Loop, Michèle |e verfasserin |4 aut | |
| 700 | 1 | |a Maes, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Philippet, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Sariban, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Van Geet, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Ferster, Alina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d 1946 |g 105(2005), 7 vom: 01. Apr., Seite 2685-90 |w (DE-627)NLM000014761 |x 1528-0020 |7 nnns |
| 773 | 1 | 8 | |g volume:105 |g year:2005 |g number:7 |g day:01 |g month:04 |g pages:2685-90 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 105 |j 2005 |e 7 |b 01 |c 04 |h 2685-90 | ||